[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620897":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":29,"centralContacts":33,"locations":40,"responsibleParty":255,"collaborators":38,"id":257,"slug":38,"hasResults":258,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":38,"eligibilityCriteria":262,"healthyVolunteers":258,"sex":263,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":38,"studyType":269,"phases":270,"briefSummary":272,"conditions":273,"keywords":38,"overallStatus":43,"whyStopped":38,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":285},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1 Prime Dose Escalation Panels","EXPERIMENTAL","Participants will receive single intravenous (IV) doses of MK-1045 at varying dose levels.",[13],"Biological: MK-1045",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2 Step-up Dose Escalation Panels","Participants will receive 3 step up doses of MK-1045 as a prime, step-up and target dose over a 3-week dosing interval.",[13],{"label":19,"type":10,"description":16,"interventionNames":20},"Part 3 Dose Expansion Panels (Optional)",[13],[22],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"BIOLOGICAL","MK-1045","IV infusion",[9,15,19],[28],"CN201",[30],{"name":31,"affiliation":5,"role":32},"Medical Director","STUDY_DIRECTOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Toll Free Number","CONTACT","1-888-577-8839",null,"Trialsites@msd.com",[41,58,72,85,99,112,126,139,152,165,179,191,200,207,220,233,246],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Gold Coast University Hospital ( Site 1601)","RECRUITING","Southport","Queensland","4215","Australia",{"type":49,"coordinates":50},"Point",[51,52],153.39796,-27.96724,{"lat":52,"lon":51},[55],{"name":56,"role":36,"phone":57,"phoneExt":38,"email":38},"Study Coordinator","+611300744284",{"facility":59,"status":43,"city":60,"state":61,"zip":62,"country":63,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Anima Diepenbeek ( Site 0601)","Diepenbeek","Limburg","3590","Belgium",{"type":49,"coordinates":65},[66,67],5.41875,50.90769,{"lat":67,"lon":66},[70],{"name":56,"role":36,"phone":71,"phoneExt":38,"email":38},"+3211949115",{"facility":73,"status":43,"city":74,"state":75,"zip":76,"country":63,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"UZ Gent ( Site 0602)","Ghent","Oost-Vlaanderen","9000",{"type":49,"coordinates":78},[79,80],3.71667,51.05,{"lat":80,"lon":79},[83],{"name":56,"role":36,"phone":84,"phoneExt":38,"email":38},"+3293322863",{"facility":86,"status":43,"city":87,"state":88,"zip":89,"country":90,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Chinese Academy of Medical Science Peking Union Medical College Hospital ( Site 1501)","Beijing","Beijing Municipality","100005","China",{"type":49,"coordinates":92},[93,94],116.39723,39.9075,{"lat":94,"lon":93},[97],{"name":56,"role":36,"phone":98,"phoneExt":38,"email":38},"010-69151188",{"facility":100,"status":43,"city":101,"state":102,"zip":103,"country":90,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1504)","Wuhan","Hubei","430058",{"type":49,"coordinates":105},[106,107],114.26667,30.58333,{"lat":107,"lon":106},[110],{"name":56,"role":36,"phone":111,"phoneExt":38,"email":38},"027-84397521",{"facility":113,"status":43,"city":114,"state":115,"zip":116,"country":117,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Clinica de la Costa S.A.S. ( Site 0101)","Barranquilla","Atlántico","080020","Colombia",{"type":49,"coordinates":119},[120,121],-74.78132,10.96854,{"lat":121,"lon":120},[124],{"name":56,"role":36,"phone":125,"phoneExt":38,"email":38},"+576053369999",{"facility":127,"status":43,"city":128,"state":129,"zip":130,"country":117,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Oncomédica S.A.S ( Site 0103)","Montería","Departamento de Córdoba","230002",{"type":49,"coordinates":132},[133,134],-75.87823,8.75081,{"lat":134,"lon":133},[137],{"name":56,"role":36,"phone":138,"phoneExt":38,"email":38},"+57 3106175733",{"facility":140,"status":43,"city":141,"state":142,"zip":143,"country":117,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Fundacion Valle del Lili ( Site 0102)","Cali","Valle del Cauca Department","760032",{"type":49,"coordinates":145},[146,147],-76.5199,3.43054,{"lat":147,"lon":146},[150],{"name":56,"role":36,"phone":151,"phoneExt":38,"email":38},"+573166237452",{"facility":153,"status":43,"city":154,"state":38,"zip":155,"country":156,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"Arensia Exploartory Medicine ( Site 1301)","Tbilisi","0112","Georgia",{"type":49,"coordinates":158},[159,160],44.83412,41.69143,{"lat":160,"lon":159},[163],{"name":56,"role":36,"phone":164,"phoneExt":38,"email":38},"+995568404374",{"facility":166,"status":43,"city":167,"state":168,"zip":169,"country":170,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Istituto Clinico Humanitas- IRCCS ( Site 1902)","Rozzano","Milano","20089","Italy",{"type":49,"coordinates":172},[173,174],9.1559,45.38193,{"lat":174,"lon":173},[177],{"name":56,"role":36,"phone":178,"phoneExt":38,"email":38},"+390282247421",{"facility":180,"status":43,"city":181,"state":38,"zip":182,"country":170,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"UOC Reumatologia ed immunologia clinica ( Site 1901)","Roma","00168",{"type":49,"coordinates":184},[185,186],11.10642,44.99364,{"lat":186,"lon":185},[189],{"name":56,"role":36,"phone":190,"phoneExt":38,"email":38},"+390630157807",{"facility":192,"status":43,"city":193,"state":194,"zip":195,"country":196,"cosmosGeoPoint":38,"geoPoint":38,"contacts":197},"The University of Tokyo Hospital ( Site 0301)","Bunkyo","Tokyo","113-8655","Japan",[198],{"name":56,"role":36,"phone":199,"phoneExt":38,"email":38},"+81-3-3815-5411",{"facility":201,"status":43,"city":202,"state":194,"zip":203,"country":196,"cosmosGeoPoint":38,"geoPoint":38,"contacts":204},"Keio University Hospital ( Site 0302)","Shinjyuku","160-8582",[205],{"name":56,"role":36,"phone":206,"phoneExt":38,"email":38},"+81-3-3353-1211",{"facility":208,"status":43,"city":209,"state":38,"zip":210,"country":211,"cosmosGeoPoint":212,"geoPoint":216,"contacts":217},"PMSI Republican Clinical Hospital \"T.Mosneaga\" ( Site 1001)","Chisinau","2025","Moldova",{"type":49,"coordinates":213},[214,215],28.85938,47.00902,{"lat":215,"lon":214},[218],{"name":56,"role":36,"phone":219,"phoneExt":38,"email":38},"+37379638895",{"facility":221,"status":43,"city":222,"state":222,"zip":223,"country":224,"cosmosGeoPoint":225,"geoPoint":229,"contacts":230},"ARENSIA Clinics ( Site 0902)","Bucharest","011658","Romania",{"type":49,"coordinates":226},[227,228],26.10626,44.43225,{"lat":228,"lon":227},[231],{"name":56,"role":36,"phone":232,"phoneExt":38,"email":38},"40722604155",{"facility":234,"status":43,"city":235,"state":236,"zip":237,"country":224,"cosmosGeoPoint":238,"geoPoint":242,"contacts":243},"ARENSIA Exploratory Medicine-Country Emergency Hospital- Arensia,Cluj-Napoca ( Site 0901)","Cluj-Napoca","Cluj","400006",{"type":49,"coordinates":239},[240,241],23.6,46.76667,{"lat":241,"lon":240},[244],{"name":56,"role":36,"phone":245,"phoneExt":38,"email":38},"+40745381603",{"facility":247,"status":43,"city":248,"state":249,"zip":250,"country":251,"cosmosGeoPoint":38,"geoPoint":38,"contacts":252},"Chulalongkorn University ( Site 0501)","Pathumwan","Bangkok","10330","Thailand",[253],{"name":56,"role":36,"phone":254,"phoneExt":38,"email":38},"+6622516704",{"type":256,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100620897",false,"NCT07363590","A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)","A Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1045 in Participants With Systemic Lupus Erythematosus and Rheumatoid Arthritis","Inclusion Criteria:\n\n* Has a body mass index between 18 and 32 kg\u002Fm\\^2, inclusive\n* Systemic lupus erythematosus (SLE): Has a diagnosis of SLE for at least 6 months and met the European Alliance of Associations for Rheumatology (EULAR)\u002F American College of Rheumatology (ACR) 2019 classification criteria\n* SLE: Is taking at least one background therapy for SLE\n* RA: Has a diagnosis of RA for at least 6 months and meets the 2010 ACR-EULAR classification criteria for RA\n\nExclusion Criteria:\n\n* Has a known active infection (excluding fungal infection of nail beds), or any major episode of infection requiring hospitalization or treatment with anti-infectives within 8 weeks prior to the Day 1 dosing\n* History of serious recurrent or chronic infection\n* Is known to be infected with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus\n* Has evidence of active tuberculosis (TB), latent TB, or inadequately treated TB\n* Has a significant or uncontrolled medical disease in any organ system not related to RA or SLE\n* For RA participants, has a history of any arthritis with onset before age 17 years\n* Has a current inflammatory condition other than SLE or RA that could interfere with disease activity assessments\n* History of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \\\u003C5 years before Day 1 dosing\n* Has had a major surgery within 3 months prior to Screening or has a major surgery planned during the study.\n* Has symptomatic heart failure (New York Heart Association class III or IV) or myocardial infarction or unstable angina pectoris within 6 months prior to Screening\n* Has a severe chronic pulmonary disease requiring oxygen therapy\n* Has current active lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease","ALL","18 Years","75 Years",{"count":267,"type":268},21,"ESTIMATED","INTERVENTIONAL",[271],"PHASE1","This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts).",[274,275],"Systemic Lupus Erythematosus","Rheumatoid Arthritis","2026-06-19",{"date":278,"type":279},"2026-06-23","ACTUAL",{"date":281,"type":279},"2026-02-19",{"date":283,"type":268},"2029-07-16",{"name":5,"class":6},17]